Dr. Joel Cooper accepted to be new Medical Advisor to XVIVO

Dr. Joel Cooper became the first surgeon in the world to complete the first successful lung transplant.  Dr. Cooper, who recently accepted an appointment to become the Medical Advisor to XVIVO Perfusion, is an internationally recognized surgeon and scientist renowned for his pioneering techniques and progress in the treatment of lung diseases. This year, the 6th of November, the medical field of transplantation celebrates the 30th anniversary of the first successful lung transplantation performed by Dr. Cooper and his surgical team at the University of Toronto. In 1983, November 7, the world´s first successful single-lung transplant operation was performed at Toronto General Hospital by a team led by Dr. Joel Cooper. The patient lived an active life for 6 years before passing away from kidney failure at the age of 64. Some years later Dr. Cooper also performed the world´s first successful clinical double lung transplants in St Louis, Missouri, USA. Dr. Cooper, who recently accepted an appointment to be the Medical Advisor to XVIVO Perfusion, is an internationally recognized surgeon and scientist who has dedicated his time and work in experimental and clinical lung transplantation. He is known for his pioneering techniques and has received numerous honors and prestigious awards over the years. Dr. Cooper is member of editorial boards, author and coauthor of more than 400 peer-reviewed scientific articles. Besides lung transplantation, Dr Cooper’s main clinical interests include general thoracic surgery, lung volume reduction surgery for emphysema, myasthenia gravis, gastro esophageal reflux, and esophageal cancer. Dr. Cooper recently stepped down from his position as the Chief of the Division of Thoracic Surgery at UPHS, Philadelphia, Pennsylvania, USA. Prior to Dr Cooper´s position at UPHS, Dr. Cooper served as the Professor of Surgery and Chief of the Division of Cardiothoracic Surgery at Washington University and Barnes-Jewish Hospital in St. Louis and before that as Surgical Director of the lung transplant group at Toronto General Hospital. Dr. Cooper will be working as Medical Advisor for XVIVO, specifically in Research and Development for new products and solutions in lung transplantation. “We are very excited that Dr. Cooper accepted the position of Medical Advisor for XVIVO. Dr. Cooper’s pioneering work in developing clinical lung transplantation to what it is today was indeed ground breaking. Dr. Cooper’s work has always been in the forefront both in terms of basic and clinical research and development and many of today’s leaders have been fostered under his supervision. Since Dr. Cooper has great knowledge, experience and contacts in the field of thoracic surgery we are very excited to have the opportunity to develop a close relationship with him and are certain that it will help XVIVO to further develop the company’s core technology – Ex Vivo perfusion of organs at normothermic temperatures.” says Dr. Magnus Nilsson, CEO, XVIVO Perfusion. October 25, 2013 Gothenburg XVIVO Perfusion AB (publ) For further information please contact: Christoffer Rosenblad, CFO, tel: +46 31 788 21 59, e-mail: christoffer.rosenblad@xvivoperfusion.com For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 25, 2013 at 10:30 a.m. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. ________________________________________________________________________________ _ _____________________________________ XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se. ________________________________________________________________________________ _ _____________________________________ XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: 46 31 788 21 50. Fax: 46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com